Company: CRL
Filing Date: 2025-11-05
Form Type: 10-Q
Source: 0001100682-25-000043
Chunk: 32

Company: CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
Filing Date: 2025-11-05
Form: 10-Q
Item: Item 2
Chunk 32
---
,544 $7,009 25.4 %3.6 %Operating income % of revenue16.2 %13.9 %230 bps

RMS revenue increased $15.7 million primarily driven by an increase in large research model product revenue, notably from Noveprim and within China, and the effect of changes in foreign currency exchange rates.

RMS operating income increased $7.0 million compared to the corresponding period in 2024. RMS operating income as a percentage of revenue for the three months ended September 27, 2025 was 16.2%, an increase of 230 bps from 13.9% for the corresponding period in 2024. Operating income and operating income as a percentage of revenue increased primarily due to the increase in revenue described above; partially offset by an increase in cost of revenue related to the amortization of an inventory step up and certain biological assets from the Noveprim acquisition compared to the corresponding period in 2024.

29 

CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

DSA

Three Months EndedSeptember 27, 2025September 28, 2024$ change% changeImpact of FX(in thousands, except percentages)Revenue$600,685 $615,060 $(14,375)(2.3)%1.2 %Cost of revenue (excluding amortization of intangible assets)408,112 409,684 (1,572)(0.4)%Selling, general and administrative56,266 63,260 (6,994)(11.1)%Amortization of intangible assets13,154 15,680 (2,526)(16.1)%Operating income$123,153 $126,436 $(3,283)(2.6)%0.8 %Operating income % of revenue20.5 %20.6 %(10) bps

DSA revenue decreased $14.4 million primarily due to lower volume driven by continued cautious client spending as a result of the current demand environment; partially offset by the effect of changes in foreign currency exchange rates compared to the corresponding period in 2024.

DSA operating income decreased $3.3 million during the three months ended September 27, 2025 compared to the corresponding period in 2024. DSA operating income as a percentage of revenue for the three months ended September 27, 2025 was 20.5%, a decrease of